Butylamine

Butylamine

SCHEMBL6473376

CCCCN.CCCCN.CCCCN.CCCCN.F.F.F.F

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 0.67
TSHR P16473 3/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
ALDH1A1 P00352 1/20 0.67
EPHX1 P07099 1/20 0.67
LMNA P02545 1/20 0.46
NFKB1 P19838 1/20 0.46
GABBR2 O75899 1/20 0.43
GABRR1 P24046 1/20 0.43
GABBR1 Q9UBS5 1/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA3 P07451 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butylamine SCHEMBL34462087 1.00 DNM1 (0.67) DNM1TSHRMEN1KMT2AALDH1A1
Butylamine SCHEMBL332657 1.00
Butylamine SCHEMBL6234410 1.00
Butylamine SCHEMBL8142996 0.96 DNM1 (0.62) DNM1TSHRMEN1KMT2AALDH1A1
Butylamine SCHEMBL2051232 0.96
Butylamine SCHEMBL28735842 0.96 DNM1 (0.62) DNM1TSHRMEN1KMT2AALDH1A1
Butylamine SCHEMBL571241 0.96
Butylamine SCHEMBL10449621 0.96
Butylamine SCHEMBL27785480 0.96 DNM1 (0.62) DNM1TSHRMEN1KMT2AALDH1A1
Butylamine SCHEMBL8559 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606634-B2 Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-04-21 US disclosed
US-12350344-B2 Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-07-08 US disclosed
US-20250114647-A1 ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-04-10 US disclosed
US-12246196-B2 Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-03-11 US disclosed
US-20240299573-A1 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-09-12 US disclosed
US-11628223-B2 Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-04-18 US disclosed
US-20230084707-A1 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-03-16 US disclosed
US-11583590-B2 Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-21 US disclosed
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES DHANOA DALJIT SINGH (US) 2023-02-09 US disclosed
US-20220395579-A1 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-12-15 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed
WO-2005012209-A2 CATALYZED ENANTIOSELECTIVE TRANSFORMATION OF ALKENES UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2005-02-10 WO disclosed
EP-1001934-B1 INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER (US) 2002-11-27 EP disclosed
US-6300363-B1 USEFUL IN THE TREATMENT OR ALLEVIATION OF INFLAMMATION AND OTHER INFLAMMATION ASSOCIATED DISORDERS IN MAMMALS PFIZER INC. 2001-10-09 US disclosed
EP-1001934-A1 INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 2000-05-24 EP disclosed
WO-1999005104-A1 INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 1999-02-04 WO disclosed
US-4588823-A 9-substituted carbacyclin analogs THE UPJOHN COMPANY (US) 1986-05-13 US disclosed
US-4487961-A ANTIULCER, ANTIASTHMA, ANTICOAGULANTS THE UPJOHN COMPANY (US) 1984-12-11 US disclosed
EP-0086611-A1 9-Substituted carbacyclin analogues THE UPJOHN COMPANY (US) 1983-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES AGTR2, AGTR1, EDNRA DNM1 1064/4885TSHR 253/4885MEN1 3228/4885
US-12606634-B2 Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 SIGLEC9, DSG1, VSIG8 DNM1 933/4885TSHR 831/4885MEN1 3455/4885
US-20240299573-A1 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE PDCD6, EPCAM, CNTN1 DNM1 738/4885TSHR 2286/4885MEN1 3170/4885
US-11628223-B2 Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines GABRA1, GABRA4, GABRA2 DNM1 179/4885TSHR 1229/4885MEN1 2164/4885
US-12350344-B2 Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate EPCAM, PDCD6, JUP DNM1 649/4885TSHR 1915/4885MEN1 1912/4885
US-12246196-B2 Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines CNTN1, BTN3A1, FABP6 DNM1 249/4885TSHR 3000/4885MEN1 3311/4885
US-20230084707-A1 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE PDCD6, EPCAM, CNTN1 DNM1 738/4885TSHR 2286/4885MEN1 3170/4885
US-20250114647-A1 ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES CNTN1, BTN3A1, FABP6 DNM1 246/4885TSHR 3001/4885MEN1 3322/4885
US-11583590-B2 Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor EPCAM, PDCD6, CNTN1 DNM1 457/4885TSHR 1841/4885MEN1 1863/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 DNM1 3247/4885TSHR 535/4885MEN1 3871/4885
US-20220395579-A1 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE PDCD6, EPCAM, CNTN1 DNM1 738/4885TSHR 2286/4885MEN1 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.